{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T02:36:52Z","timestamp":1781491012500,"version":"3.54.1"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1097\/fpc.0b013e328313aaa4","type":"journal-article","created":{"date-parts":[[2008,10,14]],"date-time":"2008-10-14T07:34:46Z","timestamp":1223969686000},"page":"1009-1015","source":"Crossref","is-referenced-by-count":53,"title":["Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin"],"prefix":"10.1097","volume":"18","author":[{"given":"Corine","family":"Ekhart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd","family":"Rodenhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul H.M.","family":"Smits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D.R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210212","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJMoa022794","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer","volume":"349","author":"Rodenhuis","year":"2003","journal-title":"N Engl J Med"},{"key":"R2-9-20210212","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1023\/A:1008328012040","article-title":"A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission","volume":"10","author":"Rodenhuis","year":"1999","journal-title":"Ann Oncol"},{"key":"R3-9-20210212","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1093\/annonc\/mdl001","article-title":"Efficacy of high-dose alkylating chemotherapy in HER2\/neu-negative breast cancer","volume":"17","author":"Rodenhuis","year":"2006","journal-title":"Ann Oncol"},{"key":"R4-9-20210212","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/sj.bmt.1703105","article-title":"Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer","volume":"28","author":"Schrama","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"R5-9-20210212","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/sj.bjc.6601001","article-title":"Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience","volume":"88","author":"Schrama","year":"2003","journal-title":"Br J Cancer"},{"key":"R6-9-20210212","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/annonc\/mdf052","article-title":"Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin","volume":"13","author":"Huitema","year":"2002","journal-title":"Ann Oncol"},{"key":"R7-9-20210212","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/sj.bjc.6603097","article-title":"High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy","volume":"94","author":"de Jonge","year":"2006","journal-title":"Br J Cancer"},{"key":"R8-9-20210212","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200544110-00003","article-title":"Clinical pharmacokinetics of cyclophosphamide","volume":"44","author":"de Jonge","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"R9-9-20210212","first-page":"4616","article-title":"Glutathione-dependent biotransformation of the alkylating drug thiotepa and transport of its metabolite monoglutathionylthiotepa in human MCF-7 breast cancer cells","volume":"58","author":"Cnubben","year":"1998","journal-title":"Cancer Res"},{"key":"R10-9-20210212","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2165\/00003088-199121040-00002","article-title":"Clinical pharmacokinetics of carboplatin","volume":"21","author":"Van der Vijgh","year":"1991","journal-title":"Clin Pharmacokinet"},{"key":"R11-9-20210212","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/00008571-200210000-00006","article-title":"Allelic variants of the human glutathione S-transferase P1 gene confer differential cytoprotection against anticancer agents in Escherichia coli","volume":"12","author":"Ishimoto","year":"2002","journal-title":"Pharmacogenetics"},{"key":"R12-9-20210212","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1006\/gyno.1996.4593","article-title":"Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer","volume":"65","author":"Tanner","year":"1997","journal-title":"Gynecol Oncol"},{"key":"R13-9-20210212","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/oxfordjournals.annonc.a058111","article-title":"Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, cyclophosphamide and thiotepa","volume":"3","author":"Rodenhuis","year":"1992","journal-title":"Ann Oncol"},{"key":"R14-9-20210212","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0140-6736(98)01350-6","article-title":"Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement","volume":"352","author":"Rodenhuis","year":"1998","journal-title":"Lancet"},{"key":"R15-9-20210212","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1200\/JCO.1996.14.5.1473","article-title":"Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer","volume":"14","author":"Rodenhuis","year":"1996","journal-title":"J Clin Oncol"},{"key":"R16-9-20210212","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1158\/1078-0432.273.11.1","article-title":"Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy","volume":"11","author":"de Jonge","year":"2005","journal-title":"Clin Cancer Res"},{"key":"R18-9-20210212","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1128\/JCM.28.3.495-503.1990","article-title":"Rapid and simple method for purification of nucleic acids","volume":"28","author":"Boom","year":"1990","journal-title":"J Clin Microbiol"},{"key":"R19-9-20210212","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00008571-200107000-00004","article-title":"Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver","volume":"11","author":"Lang","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R20-9-20210212","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00008571-199608000-00007","article-title":"The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism","volume":"6","author":"Sullivan-Klose","year":"1996","journal-title":"Pharmacogenetics"},{"key":"R21-9-20210212","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0076-6879(96)72025-6","article-title":"Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism","volume":"272","author":"Goldstein","year":"1996","journal-title":"Methods Enzymol"},{"key":"R22-9-20210212","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2000.104391","article-title":"CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity","volume":"67","author":"Sata","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"R23-9-20210212","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/clinchem\/48.10.1668","article-title":"CYP3A5 variant allele frequencies in Dutch Caucasians","volume":"48","author":"van Schaik","year":"2002","journal-title":"Clin Chem"},{"key":"R24-9-20210212","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/00008571-200111000-00004","article-title":"Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression","volume":"11","author":"Coles","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R25-9-20210212","first-page":"445","article-title":"I105\u2009V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma","volume":"11","author":"Jeronimo","year":"2002","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R26-9-20210212","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0169-5002(02)00537-8","article-title":"Association between glutathione S-transferase p1 polymorphisms and lung cancer risk in Caucasians: a case-control study","volume":"40","author":"Wang","year":"2003","journal-title":"Lung Cancer"},{"key":"R27-9-20210212","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1182\/blood-2003-02-0444","article-title":"Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma","volume":"102","author":"Dasgupta","year":"2003","journal-title":"Blood"},{"key":"R28-9-20210212","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/01.ALC.0000087086.50089.59","article-title":"Evaluation of aldehyde dehydrogenase 1 promoter polymorphisms identified in human populations","volume":"27","author":"Spence","year":"2003","journal-title":"Alcohol Clin Exp Res"},{"key":"R29-9-20210212","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/ijc.10896","article-title":"Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment","volume":"103","author":"Sweeney","year":"2003","journal-title":"Int J Cancer"},{"key":"R30-9-20210212","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF03256456","article-title":"Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population","volume":"10","author":"Bosch","year":"2006","journal-title":"Mol Diagn Ther"},{"key":"R31-9-20210212","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/00008571-199706000-00006","article-title":"Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation","volume":"7","author":"Chang","year":"1997","journal-title":"Pharmacogenetics"},{"key":"R32-9-20210212","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"R33-9-20210212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0009-2797(00)00211-8","article-title":"Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism","volume":"129","author":"Vasiliou","year":"2000","journal-title":"Chem Biol Interact"},{"key":"R34-9-20210212","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1159\/000028400","article-title":"Polymorphisms of human aldehyde dehydrogenases. Consequences for drug metabolism and disease","volume":"61","author":"Vasiliou","year":"2000","journal-title":"Pharmacology"},{"key":"R35-9-20210212","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2174\/1381612805666230110215319","article-title":"Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines","volume":"5","author":"Sladek","year":"1999","journal-title":"Curr Pharm Des"},{"key":"R36-9-20210212","first-page":"731","article-title":"Cytochrome P450 polymorphism as a predictor of ovarian toxicity to pulse cyclophosphamide in systemic lupus erythematosus","volume":"34","author":"Singh","year":"2007","journal-title":"J Rheumatol"},{"key":"R37-9-20210212","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/art.20338","article-title":"Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis","volume":"50","author":"Takada","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R38-9-20210212","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/sj.tpj.6500330","article-title":"Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19","volume":"5","author":"Timm","year":"2005","journal-title":"Pharmacogenomics J"},{"key":"R39-9-20210212","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1365-2125.2006.02690.x","article-title":"Relationship of glutathione S-transferase genotypes with side-effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus","volume":"62","author":"Zhong","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"R40-9-20210212","first-page":"4377","article-title":"Pharmacogenetic analysis of liver toxicity after busulfan\/cyclophosphamide-based allogeneic hematopoietic stem cell transplantation","volume":"27","author":"Goekkurt","year":"2007","journal-title":"Anticancer Res"},{"key":"R41-9-20210212","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1177\/0091270003260332","article-title":"Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion","volume":"43","author":"Smith","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"R42-9-20210212","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1124\/dmd.30.8.875","article-title":"Kinetic analysis of the reactions of 4-hydroperoxycyclophosphamide and acrolein with glutathione, mesna, and WR-1065","volume":"30","author":"Tacka","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"R43-9-20210212","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.freeradbiomed.2004.02.067","article-title":"Effects of cyclophosphamide and buthionine sulfoximine on ovarian glutathione and apoptosis","volume":"36","author":"Lopez","year":"2004","journal-title":"Free Radic Biol Med"},{"key":"R44-9-20210212","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/FPC.0b013e3282fc9766","article-title":"Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide","volume":"18","author":"Ekhart","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"R45-9-20210212","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1200\/JCO.2006.10.4752","article-title":"Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer","volume":"25","author":"Marsh","year":"2007","journal-title":"J Clin Oncol"},{"key":"R46-9-20210212","first-page":"679","article-title":"Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer","volume":"1","author":"Booton","year":"2006","journal-title":"J Thorac Oncol"},{"key":"R47-9-20210212","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/COC.0b013e31805c139a","article-title":"Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044)","volume":"30","author":"Jatoi","year":"2007","journal-title":"Am J Clin Oncol"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/01213011-200811000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T11:51:27Z","timestamp":1684583487000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-200811000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0b013e328313aaa4","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}